Suppressing LPA1 activity with AM966 (another specific antagonist for LPA1 [167]) not only can reverse microglial activation but can also improve long-term neurobehavioral functions following ICH [166], indicating that microglial LPA1 is critically involved in the pathogenesis of ICH as in that of cerebral ischemia [160,161,162]. Here, LPAR1 is linked to Cerebral ischemia.